SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitocco, Dario, Tartaglione, Linda, Viti, Luca, Di Leo, Mauro, Pontecorvi, Alfredo, Caputo, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179491/
https://www.ncbi.nlm.nih.gov/pubmed/32335097
http://dx.doi.org/10.1016/j.diabres.2020.108162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179491/
https://www.ncbi.nlm.nih.gov/pubmed/32335097
http://dx.doi.org/10.1016/j.diabres.2020.108162

Ejemplares similares